Literature DB >> 31107831

Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey.

Jonathan G Leung1, Joseph Cusimano2, Jessica M Gannon3, Olga Milgrom3, Stephanie C Valcourt4, Joseph B Stoklosa4, Michael Kemp5, William Olsufka6,7, P Brittany Vickery8, Stephanie D Nichols9, Ericka L Crouse10, Chris Paxos11, Emily K Johnson12, Brian A Palmer12.   

Abstract

Clozapine use has declined, despite its superior antipsychotic efficacy in treatment-resistant schizophrenia. Implications for clozapine underutilization include suboptimal treatment outcomes and increased hospitalizations. Many barriers preventing the use of clozapine have been described in the literature, including suboptimal knowledge and poor perceptions. The aim of this study was to assess psychiatry prescribers' perception and knowledge of clozapine. A survey was distributed to advanced practice providers, psychiatrists, and trainees (i.e. residents and fellows) at 10 medical centers within the US and Canada. The survey asked respondents about their perception of clozapine use and assessed their pharmacotherapeutic knowledge of clozapine. Two hundred eleven individual submitted completed surveys of a possible 1152; a response rate of 18.3%. There were no statistically significant differences between the advanced practice provider plus psychiatrist groups and the trainee group for most perception (eight of nine) and knowledge (eight of nine) questions. The knowledge questions with the lowest scores pertained to clozapine reinitiation and myocarditis. The majority of all respondents (144, 68.2%) felt that clozapine prescribing was a burden. Findings of this study support the need for continued clozapine education regardless of a prescriber's age/experience. Future studies to assess barriers to clozapine prescribing should extend beyond academic centers.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31107831     DOI: 10.1097/YIC.0000000000000269

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  2 in total

1.  A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Authors:  Robert O Cotes; A Umair Janjua; Beth Broussard; David Lazris; Ayesha Khan; Yunshen Jiao; Sarah L Kopelovich; David R Goldsmith
Journal:  Community Ment Health J       Date:  2021-05-29

2.  Iranian psychiatrists' attitude towards clozapine use for patients with treatment-resistant schizophrenia: a nationwide survey.

Authors:  Leeba Rezaie; Azadeh Nazari; Roya Safari-Faramani; Shamarina Shohaimi; Habibolah Khazaie
Journal:  BMC Psychiatry       Date:  2022-08-06       Impact factor: 4.144

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.